MedTrace Logo

Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers

NCT02464670 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2019-06-28

No results posted yet for this study

Summary

This study evaluates whether INO-4212 and its components INO-4201 and INO-4202 administered intramuscularly (IM) or intradermally (ID) followed by electroporation (EP) will be well tolerated and immunogenic.

Conditions

  • Ebola Vaccine

Interventions

BIOLOGICAL

INO-4201

INO-4201 delivered IM followed by Electroporation

BIOLOGICAL

INO-4202

INO-4202 delivered IM followed by Electroporation

BIOLOGICAL

INO-4201

INO-4201 delivered ID followed by Electroporation

BIOLOGICAL

INO-4212

INO-4212 delivered IM followed by Electroporation

BIOLOGICAL

INO-4212 + INO-9012

INO-4212 + INO-9012 delivered IM followed by Electroporation

BIOLOGICAL

INO-4201 + INO-9012

INO-4201 + INO-9012 delivered ID followed by Electroporation

Sponsors & Collaborators

  • GeneOne Life Science, Inc.

    collaborator INDUSTRY

  • Defense Advanced Research Projects Agency

    collaborator FED

  • Inovio Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Scott White, MD · Inovio Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2018-05-24
Completion
2018-05-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02464670 on ClinicalTrials.gov